Global Stem Cell Manufacturing Market, By Products (Stem Cell Lines, Instruments, Consumables and Kits), Application (Research Applications, Clinical Applications, Cell and Tissue Banking and Others), End User (Biotechnology and Pharmaceutical Companies, Research Institutes and Academic Institutes, Cell Banks and Tissue Banks, Hospital and Surgical Centers and Others), Distribution Channel (Direct Sales and Third Party Distributor) – Industry Trends and Forecast to 2029
Global Stem Cell Manufacturing Market Analysis and Size
The market for stem cell manufacturing is estimated to increase rapidly over the forecast period. Some stem cell-based treatments, such as hematopoietic stem cell transplants for leukaemia and epithelial stem cell-based treatments for burns and corneal diseases, have become clinical standards of care. In recent years, advances in stem cell research have broadened the spectrum of prospective stem cell-based therapeutics. People with spinal cord injuries, type 1 diabetes, amyotrophic lateral sclerosis, cancer, Alzheimer's disease, stroke, burns, heart disease, osteoarthritis and Parkinson's disease may benefit from stem cell therapy. They could be utilized to replace cells and tissues that have been damaged or destroyed due to disease in the future.
- Data Bridge Market Research analyses that the stem cell manufacturing market was valued at USD 12,250.9 million in 2021 and is expected to reach USD 27,428.98 million by 2029, registering a CAGR of 10.60% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Global Stem Cell Manufacturing Market Definition
The stem cell manufacturing market is an upcoming and trending market in which stem cells are obtained from blood cells or parts of bone marrow that have the ability to regenerate themselves into specialized cells in the human body and are used for the development of various kinds of drugs, as well as to see the chemical effects of drugs on various cells and tissues, and to see whether these drugs can repair or replace damaged cells or tissues.
Report Scope and Market Segmentation
2022 to 2029
2020 (Customizable to 2019 - 2014)
Revenue in USD Million, Volumes in Units, Pricing in USD
Products (Stem Cell Lines, Instruments, Consumables and Kits), Application (Research Applications, Clinical Applications, Cell and Tissue Banking and Others), End User (Biotechnology and Pharmaceutical Companies, Research Institutes and Academic Institutes, Cell Banks and Tissue Banks, Hospital and Surgical Centers and Others), Distribution Channel (Direct Sales and Third Party Distributor)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Market Players Covered
BD (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Organogenesis Inc. (US), Vericel Corporation (US), ANTEROGEN. CO., LTD. (South Korea), VistaGen Therapeutics, Inc. (US), American Cryostem Corporation (US), PromoCell GmbH (Germany), Sartorius AG (Germany), ViaCyte, Inc. (US), STEM CELL Technologies, Inc. (Canada), Takeda Pharmaceutical Company Limited (Japan), DAIICHI SANKYO COMPANY, LIMITED (Japan), Bio-Techne (US), REPROCELL Inc. (India), Catalent, Inc. (US), Mesoblast Ltd (Australia), Astellas Pharma Inc. (Japan), FUJIFILM Holdings Corporation (Japan)
Stem Cell Manufacturing Market Dynamics
- Increasing venture capital investments in stem cell research
Stem cells are critical in illness management as well as specific research projects including customized medicine and genetic testing. As public and private stakeholders worldwide become more aware of stem cells' therapeutic potential and the scarcity of therapeutic treatments for orphan illnesses, they are increasingly investing in the development of stem cell-based technology.
- Rise in the prevalence of rare genetic diseases
The market for stem cell therapy is expected to develop as the prevalence of uncommon genetic illnesses rises. Rare disorders such as thalasemmia, phenylketonuria, cystic fibrosis, and others affect millions of individuals each year.
Furthermore, the rising geriatric population and surging incidences of cancer will act as a major factor influencing the growth of stem cell manufacturing market. Along with this, increasing urbanization and rising level of personal disposable income are the driving factors accelerating the growth of the stem cell manufacturing market. Also, increasing expenditure on healthcare infrastructure are the major market drivers that will further escalate the growth of stem cell manufacturing market. Additionally, increasing awareness about therapeutic potency stem cell products will cushion the market's growth rate.
- Growing market focus on mesenchymal stem cells and induced pluripotent stem cells
Moreover, the rising focus of leading market players towards mesenchymal stem cells and induced pluripotent stem cells will provide beneficial opportunities for the stem cell manufacturing market growth. Along with this, supportive regulatory framework across developing countries will propel the market's growth rate in coming years.
Moreover, growing adoption of advanced technologies and increasing the number of emerging markets will further provide beneficial opportunities for the stem cell manufacturing market growth during the forecast period.
Restraints/Challenges Global Stem Cell Manufacturing Market
- Higher operational cost associated with stem cell manufacturing and banking
Manufacturing scale-up of stem cell lines and related accessories is frequently accompanied by major technological challenges that obstruct the whole manufacturing process and result in large operational expenditures. As a result, stem cell products are frequently more expensive than pharmaceutical medications and biologics.
On the other hand, technical limitations linked with manufacturing scale-up will challenge the stem cell manufacturing market. Additionally, the lack of skilled professionals and socio-ethical concerns related to the use of allogenic and human embryonic stem cells will restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This stem cell manufacturing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the stem cell manufacturing market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Stem Cell Manufacturing Market
In collaboration with governments throughout the world, pharmaceutical and biotech businesses are working to combat the COVID-19 pandemic, from vaccine development to logistics planning. In the R&D pipeline, there are around 115 vaccine candidates and 155 compounds. In addition, routinely used medications like hydroxychloroquine have seen a significant increase in demand for COVID-19 treatment. Because many affluent countries are experiencing a shortage of these medications, the increasing demand has provided enormous prospects for COVID-19 management drug manufacturers. As a result, the stem cell manufacturing market is projected to be significantly impacted. The majority of organizations creating stem cell manufacturing technologies have improved their response to staff disruptions and issues caused by COVID-19.
- In March 2020, Invacare had announced the launch of Invacare AVIVA FX Power Wheelchair. The AVIVA brand offers a distinct look and feel that promises best-in-class design, technology, and performance. The AVIVA FX Power Wheelchair will provide current front-wheel drive users with a high-performance chair that represents a significant advancement in front-wheel drive power mobility.
Global Stem Cell Manufacturing Market Scope
The stem cell manufacturing market is segmented on the basis of products, application, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Stem Cell Lines
- Consumables and Kits
On the basis of products, global stem cell manufacturing market is segmented into stem cell lines, instruments, consumables and kits. In 2021, consumables and kits segment is expected to dominate the market due to the frequent purchase of consumables, rising stem cell research, and increasing demand for stem cell therapies.
- Research Applications
- Clinical Applications
- Cell and Tissue Banking
On the basis of application, global stem cell manufacturing market is segmented into research applications, clinical applications, cell and tissue banking and others. In 2021, research applications segment is expected to dominate market because due to the rising focus on stem cell cytology and pathophysiology research, and growing public-private funding to support stem cell product development and commercialization.
- Biotechnology and Pharmaceutical Companies
- Research Institutes and Academic Institutes
- Cell Banks and Tissue Banks
- Hospital and Surgical Centers
On the basis of end user, global stem cell manufacturing market is segmented into biotechnology and pharmaceutical companies, research institutes and academic institutes, cell banks and tissue banks, hospital and surgical centers and others. In 2021, pharmaceutical and biotechnology companies segment is expected to dominate the market due to the growing emphasis on strategic initiatives (such as acquisitions, partnerships, and collaborations) by pharma and biotech companies to expand their capabilities in stem cell research.
- Direct Sales
- Third Party Distributor
On the basis of distribution channel, global stem cell manufacturing market is segmented into direct sales and third party distributors. In 2021, direct sales segment is expected to dominate the market because of large number of players in the market.
Stem Cell Manufacturing Market Regional Analysis/Insights
The stem cell manufacturing market is analysed and market size insights and trends are provided by country, products, application, end user and distribution channel as referenced above.
The countries covered in the stem cell manufacturing market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the stem cell manufacturing market because of the presence of major key players in this region. Additionally, the growing prevalence of chronic diseases will flourish the market's growth rate in this region.
Asia-Pacific is expected to grow during the forecast period due to rising awareness about stem cell based treatment and increasing adoption of advanced technology in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The stem cell manufacturing market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for stem cell manufacturing market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the stem cell manufacturing market. The data is available for historic period 2010-2020.
Competitive Landscape and Stem Cell Manufacturing Market Share Analysis
The Stem cell manufacturing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to stem cell manufacturing market.
Some of the major players operating in the stem cell manufacturing market are:
- BD (US)
- Thermo Fisher Scientific Inc (US)
- Merck KGaA (Germany)
- Organogenesis Inc. (US)
- Vericel Corporation (US)
- ANTEROGEN. CO., LTD (South Korea)
- VistaGen Therapeutics, Inc (US)
- American Cryostem Corporation (US)
- PromoCell GmbH (Germany)
- Sartorius AG (Germany)
- ViaCyte, Inc (US)
- STEM CELL Technologies, Inc (Canada)
- Takeda Pharmaceutical Company Limited (Japan)
- DAIICHI SANKYO COMPANY, LIMITED (Japan)
- Bio-Techne (US)
- REPROCELL Inc (India)
- Catalent, Inc (US)
- Mesoblast Ltd (Australia)
- Astellas Pharma Inc (Japan)
- FUJIFILM Holdings Corporation (Japan)
Research Methodology : Global Stem Cell Manufacturing Market
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-stem-cell-manufacturing-market